Paul Edward Kelly is Director of RELMADA THERAPEUTICS, INC.. Currently has a direct ownership of 212,295 shares of RLMD, which is worth approximately $585,934. The most recent transaction as insider was on Sep 09, 2024, when has been sold 25,000 shares (Common Stock) at a price of $2.59 per share, resulting in proceeds of $64,750. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 212K
13.35% 3M change
13.35% 12M change
Total Value Held $585,934

Paul Edward Kelly Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 09 2024
BUY
Open market or private purchase
$64,750 $2.59 p/Share
25,000 Added 10.54%
212,295 Common Stock
Apr 04 2022
SELL
Open market or private sale
$300,400 $30.04 p/Share
10,000 Reduced 5.07%
187,295 Common Stock
Apr 04 2022
BUY
Exercise of conversion of derivative security
$32,400 $3.24 p/Share
10,000 Added 4.82%
197,295 Common Stock
Jan 03 2022
SELL
Exercise of conversion of derivative security
$64,800 $3.24 p/Share
20,000 Reduced 9.65%
187,295 Common Stock
Mar 09 2021
SELL
Open market or private sale
$179,400 $35.88 p/Share
5,000 Reduced 2.9%
167,295 Common Stock
Mar 09 2021
BUY
Exercise of conversion of derivative security
$16,200 $3.24 p/Share
5,000 Added 2.82%
172,295 Common Stock
Feb 24 2021
SELL
Open market or private sale
$173,150 $34.63 p/Share
5,000 Reduced 2.9%
167,295 Common Stock
Feb 24 2021
BUY
Exercise of conversion of derivative security
$16,200 $3.24 p/Share
5,000 Added 2.82%
172,295 Common Stock
Feb 16 2021
BUY
Exercise of conversion of derivative security
$30,000 $6.0 p/Share
5,000 Added 2.9%
167,295 Common Stock
Feb 09 2021
SELL
Open market or private sale
$72,994 $35.28 p/Share
2,069 Reduced 1.26%
162,295 Common Stock
Feb 08 2021
SELL
Open market or private sale
$52,560 $35.04 p/Share
1,500 Reduced 0.9%
164,364 Common Stock
Feb 08 2021
BUY
Exercise of conversion of derivative security
$11,564 $3.24 p/Share
3,569 Added 2.11%
165,864 Common Stock
Feb 02 2021
SELL
Open market or private sale
$81,118 $35.04 p/Share
2,315 Reduced 1.41%
162,295 Common Stock
Feb 01 2021
SELL
Open market or private sale
$1,085 $35.0 p/Share
31 Reduced 0.02%
164,610 Common Stock
Feb 01 2021
BUY
Exercise of conversion of derivative security
$56,201 $3.24 p/Share
17,346 Added 9.53%
164,641 Common Stock
Jan 27 2021
SELL
Open market or private sale
$163,300 $32.66 p/Share
5,000 Reduced 3.28%
147,295 Common Stock
Jan 27 2021
BUY
Exercise of conversion of derivative security
$16,200 $3.24 p/Share
5,000 Added 3.18%
152,295 Common Stock
Jan 26 2021
SELL
Open market or private sale
$24,085 $35.16 p/Share
685 Reduced 0.46%
147,295 Common Stock
Jan 25 2021
SELL
Open market or private sale
$45,851 $35.27 p/Share
1,300 Reduced 0.87%
147,980 Common Stock
Jan 22 2021
SELL
Open market or private sale
$3,758,139 $1789.59 p/Share
2,100 Reduced 1.39%
149,280 Common Stock
Jan 22 2021
BUY
Exercise of conversion of derivative security
$13,235 $3.24 p/Share
4,085 Added 2.63%
151,380 Common Stock
PEK

Paul Edward Kelly

Director
New York, NY

Track Institutional and Insider Activities on RLMD

Follow RELMADA THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLMD shares.

Notify only if

Insider Trading

Get notified when an Relmada Therapeutics, Inc. insider buys or sells RLMD shares.

Notify only if

News

Receive news related to RELMADA THERAPEUTICS, INC.

Track Activities on RLMD